New Data Highlight Benefit Of SEROQUEL Monotherapy For Long-Term Treatment Of Bipolar Disorder Part 3

SEROQUEL XRâ„¢ be official within the US and 25 further country in support of the conduct of schizophrenia in fully fledged patients and for keep treatment of schizophrenia in adult patients. It be launch in the US in 2007 and nearer this year AstraZeneca announced the submission of regulatory application in both the US and European Union for SEROQUEL XR in the treatment of manic division associated near bipolar turmoil, and the treatment of depressive episodes associated with bipolar disorder. An sNDA for SEROQUEL XR seeking verification for the treatment of Major Depressive Disorder in the US was announced in February 2008 and a equal submission in Europe was announced in June 2008. SEROQUEL XR is not approved for these warning sign immensely soon and the applications delay leaving underneath investigation via the regulatory authorities.

About AstraZeneca AstraZeneca is a primary sophisticated Healthcare conglomerate affianced in the research, encouragement, commerce and marketing of no-nonsense prescription medicine and hawker for Healthcare services. AstraZeneca is one of the world's major pharmaceutical band with Healthcare public sale of $29.55 billion and is a commandant in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and catching illness medicines. In the United States, AstraZeneca is a $13.35 billion dollar Healthcare business with 12,200 human resources committed to rising people's live. AstraZeneca is timetabled in the Dow Jones Sustainability Index (Global) moreover in forte of the FTSE4Good Index.

*Based by the side of hypothesis: (1) inexact numeral of prescription per tolerant base upon IMS APLD background; and (2) IMS Prescription data for SEROQUEL exterior 13 major market where this data is unclaimed since the circumstance of launch.

SEROQUEL XR is a trademark of the AstraZeneca bundle of companies.

References 1. Young AH, et al. Placebo-controlled organization with acute and persistence step of quetiapine in adults with bipolar collapse (EMBOLDEN I). Presented at the European College of Neuropsychopharmacology Congress, Barcelona, Spain, 30 August-3 September, 2008.

2. McElroy S, et al. Placebo-controlled study with acute and continuation phase of quetiapine in adults with bipolar depression (EMBOLDEN II). Presented at the European College of Neuropsychopharmacology Congress, Barcelona, Spain, 30 August-3 September, 2008.

3. Nolen WA. Quetiapine or lithium vs. placebo in the maintenance treatment of bipolar disorder. Data presented at an AstraZeneca satellite symposium. Barcelona, Spain, 2 September, 2008.

4. Vieta E, et al. Efficacy and sanctuary of quetiapine in muddle with lithium or divalproex for maintenance of patients with bipolar I disorder (international try-out 126). J Affect Disord 2008;109:251-63.

5. Brecher M, et al. Quetiapine in the maintenance treatment of bipolar I disorder: shared data from two long-term phase III study. Presented at the Conference of the International Society for Bipolar Disorders, Delhi, India, 27-30 January, 2008.

Astrazeneca

buy female viagra online